Form 4: DaVita Inc. CEO Javier Rodriguez Reports Acquisition of Stock and Stock Appreciation Rights
SEC Form 4
CEO Javier Rodriguez reports acquiring shares and stock appreciation rights in DaVita Inc.
Summary
- On March 15, 2025, Javier Rodriguez, the CEO of DaVita Inc., reported acquiring 18,822 shares of common stock at $0 and 52,106 stock appreciation rights.
- Following the transaction, Rodriguez directly owns 894,080 shares of common stock and 52,106 stock appreciation rights.
- The stock appreciation rights have an exercise price of $143.45 and expire on March 15, 2030.
- The stock appreciation rights and restricted stock units are scheduled to vest 50% each on March 15, 2028 and March 15, 2029, respectively, subject to the terms and conditions of the applicable award agreement.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO acquiring shares and stock appreciation rights suggests confidence, but it's a routine filing.
Positives
- The CEO's acquisition of shares and stock appreciation rights could be interpreted as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule of the restricted stock units and stock appreciation rights suggests a long-term incentive plan for the CEO, aligning his interests with the company's performance over the next several years.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and are closely watched by investors for signals about management's confidence in the company's prospects. The acquisition of shares and stock appreciation rights by the CEO is a common form of executive compensation in the healthcare industry.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded healthcare companies like DaVita.
- Companies such as UnitedHealth Group (UNH) and CVS Health (CVS) also utilize similar equity-based compensation to incentivize their executives.
- The vesting schedules and terms of these awards are generally aligned with industry norms to retain and motivate key personnel.
Stakeholder Impact
- The CEO's acquisition of shares aligns his interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
Key Dates
| Date | Description |
|---|---|
| 03/15/2025 | Date of transaction: Acquisition of common stock and stock appreciation rights. |
| 03/15/2028 | 50% vesting date for restricted stock units and stock appreciation rights. |
| 03/15/2029 | Remaining 50% vesting date for restricted stock units and stock appreciation rights. |
| 03/15/2030 | Expiration date of the stock appreciation rights. |
| 03/18/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.